Lynx1 Capital Management LP Portfolio Holdings

Lynx1 Capital Management LP

  • $338 Million
  • Q2 2025

Lynx1 Capital Management LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $338 Million distributed in 15 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Merus N.V. with a value of $82.5M, Gh Research PLC with a value of $82.2M, Stoke Therapeutics, Inc. with a value of $61.3M, Protagonist Therapeutics, Inc with a value of $40.5M, and Cullinan Oncology, Inc. with a value of $33.1M.

Examining the 13F form we can see an increase of $67.2M in the current position value, from $270M to 338M.

Lynx1 Capital Management LP is based out at San Juan, PR

Below you can find more details about Lynx1 Capital Management LP portfolio as well as his latest detailed transactions.

Portfolio value $338 Million
Healthcare: $338 Million

Stock Holdings Table Market Cap. of Under $50 Millions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$31.6M
$11.4 Million 3.37% of portfolio
7,857,347
Q2 2025 Added 46.66%

Summary

  • Portfolio
  • No. of Stocks 15
  • Current Value $338 Million
  • Prior Value $270 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 1 stocks
  • Additional Purchases 6 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 0 stocks
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email